Clinical trials: Opioid-Related Disorders
Opioid-use Disorder, Opioid Use
PRescribing INterventions for Chronic Pain Via the Electronic Health Record Study - Opioid-Naive Population
The objective of this research is to assess the effects of electronic health record (EHR)-based decision support tools on primary care provider (PCP) decision-making around pain treatment and opioid prescribing.
- Conditions
- Opioid-use Disorder, Opioid Use, Opioid Abuse
- Trial name
- PRINCE (NCT04601493)
- Testing
- Choice Architecture Nudge, PMP Integration & Nudge
- Where
- United States
- Volunteers
- 631 people
- Sponsor
- University of Minnesota
Opioid-Related Disorders, Neuralgia
Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection
Using combination of opioid analgesics and analgesics with different mechanism of action the investigators can decrease the consumption of opioid analgesics and their side effects.
- Trial name
- NCT02616523
- Testing
- Dexmedetomidine, Lidocaine, Fentanyl
- Volunteers
- 60 people
- Sponsor
- University Medical Centre Ljubljana
Opioid-use Disorder, Opioid Dependence
SMART Effectiveness Trial
The current study piloted two psychosocial interventions developed to increase buprenorphine-naloxone adherence in individuals with opioid use disorder (OUD).
- Conditions
- Opioid-use Disorder, Opioid Dependence, Treatment Adherence
- Trial name
- NCT04464421
- Testing
- Contingency Management (CM), Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Karen Derefinko, PhD
Opioid Use Disorder, Opioid Dependence
Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients
The purpose of this study is to examine whether buprenorphine can be at least as effective as other opioid medications in relieving chronic pain in patients who suffer from dependence on their opioid medications, while patients…
- Conditions
- Opioid Use Disorder, Opioid Dependence, Chronic Pain
- Trial name
- NCT01841931
- Testing
- Buprenorphine/Naloxone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Theresa Jacob, PhD, MPH
Opioid Use Disorder, Chronic Pain
An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment
Severe chronic pain and opioid use disorder (OUD) occur at significantly higher rates in Veterans compared to the general population.
- Trial name
- NCT05051644
- Testing
- Steps 2 Change (S2C), Control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- VA Office of Research and Development
Opioid Use Disorder
Cannabidiol in the Treatment of Opioid Use Disorder
The long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD).
- Trial name
- NCT06206291
- Testing
- Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Yasmin Hurd
Opioid-Related Disorders, Opiate Addiction
Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain
The purpose of this study is to evaluate the effect on pain intensity (PI) of structured discontinuation of long-term opioid analgesic therapy compared to continuation of opioid therapy in Suboptimal and Optimal Responders to…
- Conditions
- Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02741076
- Testing
- Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER), Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
- Where
- 61 sites in United States
- Volunteers
- 44 people
- Sponsor
- Member Companies of the Opioid PMR Consortium
Opioid Use
Prevention Interventions for Opioid Misuse
The purpose of the study is to develop and test innovative interventions to prevent the development of opioid misuse and opioid use disorders among older adolescents and young adults (AYA; ages 16-30) who use opioids, which will…
- Trial name
- NCT04550715
- Testing
- Brief intervention (BI), Portal, Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 1,155 people
- Sponsor
- University of Michigan
Opioid Abuse
Community Trial in the Cherokee Nation
The target population is students attending high schools in small rural towns in the 14 counties that partially or fully fall within the Cherokee Nation reservation.
- Trial name
- NCT04839978
- Testing
- Connect Program, Communities Mobilizing for Change and Action (CMCA)
- Where
- United States
- Volunteers
- 919 people
- Sponsor
- Emory University
Opioid Dependence
Dronabinol Naltrexone Treatment for Opioid Dependence
The goal of this two-year study is to test the efficacy of dronabinol as an adjunct to maintenance treatment with naltrexone in opioid-dependent individuals.
- Trial name
- Domino (NCT01024335)
- Testing
- injectable naltrexone and dronabinol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Substance Use Disorders, Infection, Soft Tissue
Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use
Standard of care for patients with opioid use disorder and complicated infections is discharge to subacute nursing facilities on IV antibiotics until completion of treatment course.
- Conditions
- Substance Use Disorders, Infection, Soft Tissue, Bacteremia, Osteomyelitis Acute
- Trial name
- AIM-STOP (NCT05521880)
- Testing
- Oritavancin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Maryland, Baltimore
Opioid-use Disorder, Contingency Management
Usability Testing for the Reward-based Technology to Improve OUD Treatment
Millions of people in the US misuse opioids each year, leading to thousands of deaths and costing billions of dollars in total economic burden.
- Conditions
- Opioid-use Disorder, Contingency Management, Medication for Opioid-use Disorder
- Trial name
- OARSCM (NCT05159362)
- Testing
- Software Application
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Q2i, LLC
Opioid Use Disorder, Alcohol Use Disorder
Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study
The purpose of this study is to learn how best to treat substance use disorders in an HIV clinic setting. Specifically, the purpose of this pilot study is to learn if extended-release naltrexone (XR-NTX) would be a feasible and…
- Trial name
- CHOICES (NCT01908062)
- Testing
- Extended Release Naltrexone, Treatment As usual
- Where
- 2 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Oregon Health and Science University
Drug Use Disorders, Drug Abuse
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
Background: Sixty million American adults suffer from moderate to severe chronic pain. Of these, 5 to 8 million currently use opioids long-term.
- Conditions
- Drug Use Disorders, Drug Abuse, Drug Addiction, Drug Dependence
- Trial name
- CARE (NCT02224508)
- Volunteers
- 1,588 people
- Sponsor
- Kaiser Permanente
Opioid Use Disorder
Reward-Based Recovery Outcomes Management for Opioid Use Disorder
A randomized pilot study assessing feasibility, acceptability, and preliminary effectiveness of a reward-based recovery management platform (PROCare) designed to enhance participation in outcomes monitoring, engagement in…
- Trial name
- NCT04669249
- Testing
- PROCare
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Medical Decision Logic, Inc.
Opioid Abuse
Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
The primary objective of this study is to compare the relative abuse potential of two different doses of orally administered Acurox Tablets to orally administered immediate-release (IR) oxycodone HCl tablets in non-dependent…
- Trial name
- NCT01030406
- Testing
- 40/0mg taken first, 80/0mg taken first, 40/240mg taken first
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
Opioid Use Disorder
Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults
The purpose of this study is to evaluate the safety and blood levels of a medicine, naltrexone, contained within an implant in healthy volunteers age 18 to 65 years.
- Trial name
- NCT06216132
- Testing
- BIOPIN-6 Active Implant with Naltrexone
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Akyso Therapeutics, LLC
Opioid-use Disorder
Buprenorphine Loading in the Emergency Department
Buprenorphine (BUP) is FDA-approved for the treatment of opioid withdrawal and opioid use disorder. Few ED providers have received the necessary DEA registration (aka X waiver) required to prescribe BUP, and urgent appointments…
- Trial name
- NCT04283500
- Testing
- Buprenorphine Naloxone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- NYU Langone Health
Opioid Dependence
An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects
This is an open label study in opioid dependent subjects maintained on a stabilized dose of Suboxone tablets or films. The purpose is to assess the safety and tolerability of BEMA Buprenorphine NX administered once daily for 12…
- Trial name
- NCT01666119
- Testing
- BEMA Buprenorphine NX films
- Where
- 10 sites in United States
- Volunteers
- 249 people
- Sponsor
- BioDelivery Sciences International
Opioid Use Disorder
A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder
The primary purpose of this study was to assess the safety and tolerability of multiple doses of buprenorphine/naloxone alone and buprenorphine/naloxone in combination with a single dose of ASP8062.
- Trial name
- NCT04447287
- Testing
- ASP8062, buprenorphine/naloxone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Global Development, Inc.